![]() |
市場調查報告書
商品編碼
1423673
到 2030 年兒童用灌注系統市場預測:按產品、應用、最終用戶和地區分類的全球分析Pediatric Perfusion Systems Market Forecasts to 2030 - Global Analysis By Product, By Application (Cardiac Surgeries, Organ Transplantation, Extracorporeal Life Support and Other Applications), End User and By Geography |
2023年,全球兒童用灌注系統市場價值為3.4696億美元,預計到2030年將達到6.2616億美元,預測期內複合年成長率為8.8%。
兒童用灌注系統是專門為在心血管手術期間需要心肺體外迴圈的嬰幼兒和兒童創建的醫療裝置。這些系統是根據兒童獨特的生理機能量身量身定做,包括小型氧氣輸送機、幫浦、管道和監測設備。這些系統安全有效地支持兒童心血管手術,同時在手術過程中維持補氧、溫度調節和血液循環等關鍵功能,同時考慮年輕患者的獨特需求。
根據美國心臟協會 2022 年情況說明書,先天性心臟疾病預計每年將影響美國約 4 萬名嬰兒。
先天性心臟疾病發生率增加
全球嬰幼兒和兒童先天性心臟疾病盛行率不斷上升,是兒童用灌注系統市場的主要驅動力。由於認知的提高和診斷能力的提高,更多的病例可以更早被發現並需要先進的心血管手術。兒童用灌注系統在這些手術中發揮關鍵作用,為兒童患者的小解剖結構和獨特的生理需求提供專門的支持。由於先天性心臟疾病的增加,心血管手術的需求不斷增加,對有效灌注系統的需求也隨之增加。
設備和流程高成本
兒童用灌注系統和相關程序的高成本是市場的主要抑制因素。為兒童患者量身定做的設備的特殊性,加上嚴格的安全標準和先進技術,導致成本上升。此外,維護和升級這些系統的成本以及對高技能人員的需求進一步增加了整體成本。儘管兒童心血管手術迫切需要這些系統,但高成本限制了某些醫療機構和地區的使用,阻礙了這些系統的廣泛普及。
對客製化解決方案的需求不斷成長
兒童患者有不同的解剖和生理需求,並且越來越重視客製化系統和技術來適應這些變化。專注於適應性強、針對患者的解決方案(例如可調泵、緊湊型供氧設備和專用監測設備)的公司可以利用這一趨勢。提供滿足特定患者需求的客製化選項不僅可以改善患者的治療效果,還可以建立競爭優勢並促進兒童用灌注系統的創新和市場擴張。
快速的技術變革
快速的技術創新對市場構成威脅,因為它有可能導致現有系統過時。持續的進步可以縮短設備的生命週期並加速當前系統的淘汰。這需要頻繁升級和投資新技術,從而增加醫療機構的成本。此外,需要對員工進行更新系統培訓並確保與不斷發展的標準相容,這可能會帶來物流的挑戰。技術的快速發展可能會限制對當前解決方案的投資並影響市場穩定性。
COVID-19 的爆發干擾並影響了擇期手術市場,包括兒童心血管手術手術,這些系統在其中發揮關鍵作用。由於醫院容量減少、資源重新分配和安全措施,非緊急手術被推遲。因此,對兒童用灌注系統的需求暫時下降,影響了市場成長。然而,儘管面臨這些挑戰,許多兒童心血管手術的緊迫性仍然保持著一定的需求。
預計兒童用氧氣供應領域在預測期內將是最大的
由於兒童用氧氣輸送裝置在兒童心血管手術期間提供必要的氧氣輸送支援方面發揮關鍵作用,因此預計將佔據大部分市場。專門的氧氣輸送設備對於這些手術至關重要,因為它們需要低血容量和針對兒童獨特生理機能的精確氧氣輸送。此外,先天性心臟疾病發病率的上升和兒童心血管手術的需求正在推動對高效、適應性強的氧氣輸送設備的需求,使這一領域成為兒童用灌注系統的基石,並增加了小兒心臟手術的需求。我們優勢背後的驅動力。
預計製藥和生物技術公司在預測期內將表現出最高的複合年成長率。
由於專注於兒童用灌注系統的研究和開發的增加,製藥和生物技術領域預計將出現最高的成長率。這些公司廣泛投資於創新技術、藥物開發和兒童心血管手術專用設備。隨著對兒童患者客製化解決方案的日益重視,製藥和生物技術公司在開發先進灌注系統方面處於領先地位,推動了該領域在預測期內的預期高成長率。
由於先進的醫療基礎設施、大量的研發投資以及先天性心臟疾病的高盛行率,預計北美將佔據最大的市場佔有率。此外,該地區還設有兒童心臟中心,研究機構與製藥公司之間的協作系統也已建立。有利的報銷政策和主要市場參與者的存在進一步增強了北美在採用和實施先進兒童用灌注系統方面的優勢,確保了重要的市場佔有率。
由於醫療保健支出增加、兒童心臟護理意識增強以及兒童人口不斷成長,預計亞太地區將出現顯著成長。新興國家的醫療保健基礎設施和技術採用不斷改善,推動了對先進灌注系統的需求。此外,與全球公司的合作、政府舉措以及兒童心血管手術中心的擴張正在為該地區在先進兒童用灌注系統的實施和整合方面發揮巨大的成長潛力做出貢獻。
According to Stratistics MRC, the Global Pediatric Perfusion Systems Market is accounted for $346.96 million in 2023 and is expected to reach $626.16 million by 2030 growing at a CAGR of 8.8% during the forecast period. Pediatric perfusion systems are specialised medical setups crafted specifically for infants and children requiring cardiopulmonary bypass during cardiac surgeries. Tailored to their unique physiologies, these systems include smaller oxygenators, pumps, tubing and monitoring devices. They maintain vital functions like oxygenation, temperature control and blood circulation during procedures, ensuring safe and effective support for pediatric cardiac surgery while considering the unique needs of younger patients.
According to American Heart Association, Inc.'s fact sheet 2022, congenital heart defects are expected to affect around 40,000 infants in the U.S. each year.
Rising incidence of congenital heart defects
The increasing prevalence of congenital heart defects among infants and children globally serves as a significant driver in the pediatric Perfusion systems market. With rising awareness and improved diagnostic capabilities, more cases are being identified early, necessitating advanced cardiac surgeries. Pediatric perfusion systems play a crucial role in these surgeries, providing specialised support tailored to the smaller anatomies and unique physiological requirements of pediatric patients. As the demand for corrective cardiac procedures rises due to the growing incidence of congenital heart defects, the need for effective perfusion systems amplifies accordingly.
High cost of equipment and procedures
The high cost associated with pediatric perfusion systems and related procedures poses a significant restraint on the market. The specialised nature of equipment tailored for pediatric patients, coupled with stringent safety standards and advanced technologies, contributes to elevated costs. Additionally, the expenses incurred in maintaining and upgrading these systems, along with the need for highly skilled personnel, further escalate the overall expenditure. This high cost limits accessibility for certain healthcare facilities or regions, hindering widespread adoption despite the critical need for these systems in pediatric cardiac surgeries.
Growing demand for customized solutions
Pediatric patients exhibit diverse anatomies and physiological needs, and there's a growing emphasis on tailored systems and technologies to address these variations. Companies focusing on adaptable, patient-specific solutions, such as adjustable pumps, smaller oxygenators, and specialised monitoring devices, can capitalise on this trend. Offering customised options that cater to specific patient requirements not only enhances patient outcomes but also establishes a competitive edge, fostering innovation and market expansion in pediatric perfusion systems.
Rapid technological changes
Rapid technological changes pose a threat to the market due to the risk of rendering existing systems obsolete. Continuous advancements may lead to shorter lifecycles for equipment, potentially making current systems outdated faster. This necessitates frequent upgrades or investments in newer technologies, increasing costs for healthcare facilities. Additionally, the need for training staff on updated systems and ensuring compatibility with evolving standards can create logistical challenges. This swift pace of technological evolution might deter investments in current solutions, impacting market stability.
The COVID-19 pandemic has influenced the market by causing disruptions in elective surgeries, including pediatric cardiac procedures, where these systems are crucial. Reduced hospital capacities, redirected resources, and safety measures resulted in deferred non-emergency surgeries. This decreased demand for pediatric perfusion systems temporarily, affecting market growth. However, the urgent nature of many pediatric cardiac surgeries has sustained some demand despite these challenges.
The pediatric oxygenators segment is expected to be the largest during the forecast period
The pediatric oxygenators segment is anticipated to dominate due to its pivotal role in providing essential oxygenation support during pediatric cardiac surgeries. As these procedures require precise and tailored oxygenation for smaller blood volumes and unique pediatric physiology, specialised oxygenators are crucial. Additionally, the rising incidence of congenital heart defects and the demand for pediatric cardiac interventions drive the need for efficient and adaptable oxygenators, positioning this segment as a cornerstone in pediatric perfusion systems and thus driving its expected market dominance.
The pharmaceutical and biotech companies segment is expected to have the highest CAGR during the forecast period
The pharmaceutical and biotech companies segment anticipates the highest growth rate owing to increased research and development focused on pediatric perfusion systems. These companies invest extensively in innovative technologies, drug development and specialised equipment catering to pediatric cardiac surgeries. With a growing emphasis on tailored solutions for pediatric patients, pharmaceutical and biotech firms are leading in developing advanced perfusion systems, thus driving the projected high growth rate in this segment during the forecast period.
North America is positioned to hold the largest market share due to advanced healthcare infrastructure, substantial R&D investments, and a high prevalence of congenital heart defects. Additionally, the region boasts well-established pediatric cardiac centers and collaborations between research institutes and pharmaceutical companies. Favorable reimbursement policies and the presence of key market players further contribute to North America's dominance in adopting and implementing sophisticated pediatric perfusion systems, securing a significant market share.
The Asia-Pacific region is set to experience significant growth owing to the rising healthcare expenditure, increasing awareness about pediatric cardiac care and a growing pediatric population. Emerging economies are witnessing improvements in healthcare infrastructure and technology adoption, fostering the demand for advanced perfusion systems. Moreover, collaborations with global players, government initiatives and expanding pediatric cardiac surgery centres contribute to the region's substantial growth potential in adopting and integrating sophisticated pediatric perfusion systems.
Key players in the market
Some of the key players in Pediatric Perfusion Systems Market include Baxter International Inc., Braile Biomedica, Edwards Lifesciences Corporation, Getinge Group, Hemovent GmbH, LeMaitre Vascular, Inc., LivaNova, Medtronic, MicroPort Scientific Corporation, Nipro Medical Corporation, Perfusion.com, Inc., Sorin Group, Spectrum Medical, Stryker Corporation, Terumo Cardiovascular and Xenios AG.
In December 2023, Vascular Perfusion Solutions (VPS), Inc., is a San Antonio based medical device startup company focused on developing novel prolonged organ preservation technologies prior to transplantation, has received a $25,000 grant from the Southwest-Midwest National Pediatric Device Innovation Consortium (SWPDC).
In March 2023, LivaNova PLC, a market-leading medical technology and innovation company, announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM). With FDA clearance, LivaNova initiates the commercial launch of Essenz in the U.S. The Company also recently received approval for the Essenz HLM from Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).